 | Up a level |
Borner, M; Koeberle, D; Von Moos, R; Saletti, P; Rauch, D; Hess, V; Trojan, A; Helbling, D; Pestalozzi, B; Caspar, C; Ruhstaller, T; Roth, A; Kappeler, A; Dietrich, D; Lanz, D; Mingrone, W (2008). Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. Annals of oncology, 19(7), pp. 1288-92. Oxford: Oxford University Press 10.1093/annonc/mdn058
Helbling, D; Roth, A; Breitenstein, S; Pestalozzi, B; Mentha, G; Magno, P; Seiler, C.A.; Borner, M (2008). Kurative Therapieoptionen beim metastasierenden Kolorektalkarzinom. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, 8(45), p. 864. Basel: EMH Editores Medicorum Helveticorum
Helbling, D; Borner, M (2007). Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab. Annals of oncology, 18(5), pp. 963-4. Oxford: Oxford University Press 10.1093/annonc/mdm130
